Patent ID: 6153385
Filing Date: 2000-11-28
Classification: C12Q

Abstract:
A process for quantifying a CD95 ligand, comprising:(a) isolating RNA from cells;(b) transcribing said RNA of step (a) into cDNA by reverse transcription;(c) amplifying said cDNA of step (b) and a defined amount of CD95 ligand competitor fragment using CD95 ligand-specific primers, wherein the CD95 ligand-specific primers have the following sequences:L.sub.up 5'-ATGTTTCAGCTCTTCCACCTACAGA-3' (SEQ ID NO: 1) andL.sub.down 5'-CCAGAGAGAGCTCAGATACGTTGAC-3' (SEQ ID NO: 2), so that a CD95 ligand amplification product of the cDNA of step (b) and a CD95 ligand competitor amplification product are generated; and(d) quantifying said CD95 ligand by comparing the quantity of CD95 ligand amplification product with the quantity of CD95 ligand competitor amplification product.